Our findings facilitate prediction for prognosis and immunotherapeutic response in colon cancer, and targeting lipid metabolism reprogramming in the TME may be promising strategies for synergy with anti-PD-1 treatment. Here, PDCD1 is linked to malignant colon neoplasm.